symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
MNMD,2.94,2.258733,508000,116767686,0,2.12-5.01,0.05,Mind Medicine (MindMed) Inc.,USD,0001813814,CA60255C1095,60255C109,NASDAQ Capital Market,NASDAQ,Biotechnology,https://www.mindmed.co,"Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ÃŸ4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.",Mr. Robert  Barrow,Healthcare,CA,48,,1055 West Hastings Street,Vancouver,BC,V6E 2E9,,0,https://financialmodelingprep.com/image-stock/MNMD.png,2016-11-15,False,False,True,False,False
